中外医学研究
中外醫學研究
중외의학연구
CHINESE AND FOREIGN MEDICAL RESEARCH
2015年
11期
21-23
,共3页
杨珍旭%刘信%徐晓佳%刘泽斌%胡兰
楊珍旭%劉信%徐曉佳%劉澤斌%鬍蘭
양진욱%류신%서효가%류택빈%호란
稳定型冠心病%心绞痛%氯吡格雷%阿司匹林
穩定型冠心病%心絞痛%氯吡格雷%阿司匹林
은정형관심병%심교통%록필격뢰%아사필림
Stable coronary artery disease%Angina%Clopidogrel%Aspirin
目的:探讨氯吡格雷与阿司匹林治疗稳定型冠心病的临床疗效,以便临床更好地选择用药。方法:将笔者所在医院2012年1月-2015年1月确诊的4071例稳定型冠心病患者随机分为氯吡格雷组(2400例)和阿司匹林组(1671例)。两组患者均给予调脂、降压、控制血糖及抗心肌缺血等常规药物治疗。氯吡格雷组以服用常规药物的基础上加用氯吡格雷进行治疗,阿司匹林组以服用常规药物的基础上加用阿司匹林进行治疗,14 d为一疗程。对比两组患者治疗前后血小板聚集率(PAR);判定心绞痛及心电图临床疗效,同时比较两组患者接受治疗后粒细胞减少、心肝肾功能、出血等不良反应的发生情况。结果:治疗14 d后,氯吡格雷组的PAR降低程度大于阿司匹林组(P<0.05)。氯吡格雷组的病情恶化率3.3%(79/2400)明显低于阿司匹林组的11.5%(192/1671),比较差异有统计学意义(P<0.05)。氯吡格雷组的治疗总有效率96.7%明显高于阿司匹林组的78.2%,差异有统计学意义(P<0.05)。心电图疗效评估发现,氯吡格雷组的总有效率86.7%明显高于阿司匹林组的70.8%,差异有统计学意义(P<0.05)。治疗过程中氯吡格雷组的不良反应发生率为3.2%(76/2400)明显低于阿司匹林组的10.7%(178/1671),差异有统计学意义(P<0.05)。结论:氯吡格雷治疗稳定型冠心病的临床疗效及安全性优于阿司匹林,值得临床上推广应用。
目的:探討氯吡格雷與阿司匹林治療穩定型冠心病的臨床療效,以便臨床更好地選擇用藥。方法:將筆者所在醫院2012年1月-2015年1月確診的4071例穩定型冠心病患者隨機分為氯吡格雷組(2400例)和阿司匹林組(1671例)。兩組患者均給予調脂、降壓、控製血糖及抗心肌缺血等常規藥物治療。氯吡格雷組以服用常規藥物的基礎上加用氯吡格雷進行治療,阿司匹林組以服用常規藥物的基礎上加用阿司匹林進行治療,14 d為一療程。對比兩組患者治療前後血小闆聚集率(PAR);判定心絞痛及心電圖臨床療效,同時比較兩組患者接受治療後粒細胞減少、心肝腎功能、齣血等不良反應的髮生情況。結果:治療14 d後,氯吡格雷組的PAR降低程度大于阿司匹林組(P<0.05)。氯吡格雷組的病情噁化率3.3%(79/2400)明顯低于阿司匹林組的11.5%(192/1671),比較差異有統計學意義(P<0.05)。氯吡格雷組的治療總有效率96.7%明顯高于阿司匹林組的78.2%,差異有統計學意義(P<0.05)。心電圖療效評估髮現,氯吡格雷組的總有效率86.7%明顯高于阿司匹林組的70.8%,差異有統計學意義(P<0.05)。治療過程中氯吡格雷組的不良反應髮生率為3.2%(76/2400)明顯低于阿司匹林組的10.7%(178/1671),差異有統計學意義(P<0.05)。結論:氯吡格雷治療穩定型冠心病的臨床療效及安全性優于阿司匹林,值得臨床上推廣應用。
목적:탐토록필격뢰여아사필림치료은정형관심병적림상료효,이편림상경호지선택용약。방법:장필자소재의원2012년1월-2015년1월학진적4071례은정형관심병환자수궤분위록필격뢰조(2400례)화아사필림조(1671례)。량조환자균급여조지、강압、공제혈당급항심기결혈등상규약물치료。록필격뢰조이복용상규약물적기출상가용록필격뢰진행치료,아사필림조이복용상규약물적기출상가용아사필림진행치료,14 d위일료정。대비량조환자치료전후혈소판취집솔(PAR);판정심교통급심전도림상료효,동시비교량조환자접수치료후립세포감소、심간신공능、출혈등불량반응적발생정황。결과:치료14 d후,록필격뢰조적PAR강저정도대우아사필림조(P<0.05)。록필격뢰조적병정악화솔3.3%(79/2400)명현저우아사필림조적11.5%(192/1671),비교차이유통계학의의(P<0.05)。록필격뢰조적치료총유효솔96.7%명현고우아사필림조적78.2%,차이유통계학의의(P<0.05)。심전도료효평고발현,록필격뢰조적총유효솔86.7%명현고우아사필림조적70.8%,차이유통계학의의(P<0.05)。치료과정중록필격뢰조적불량반응발생솔위3.2%(76/2400)명현저우아사필림조적10.7%(178/1671),차이유통계학의의(P<0.05)。결론:록필격뢰치료은정형관심병적림상료효급안전성우우아사필림,치득림상상추엄응용。
Objective:To investigate the clinical efficacy of Clopidogrel and Aspirin therapy in the treatment of stable coronary heart disease,in order to select the better clinical treatment.Method:4071 cases of stable coronary artery disease diagnosed in our hospital from January 2012 to January 2015 were randomly divided into the Clopidogrel group (n=2400) and the Aspirin group (n=1671).The two groups were treated with lipid-lowering, antihypertensive treatment,hypoglycemic therapy,anti-ischemic therapy.On the the basis of conventional drugs,the Clopidogrel group was given Clopidogrel,the Aspirin group was given Aspirin.14 days for a period of treatment.Then the changes platelet aggregation rate (PAR),angina pectoris, electrocardiogram clinical efficacy,neutropenia,heart function,liver function,kidney function,hemorrhage and the occurrence of adverse reactions in the two groups after 14 days were evaluated and compared.Result:After 14 d treatment,the level of PAR decreased in the Clopidogrel group was significantly larger than that of the Aspirin group(P<0.05).The deterioration rate of the Clopidogrel group was 3.3%(79/2400),which was significantly lower than 11.5%(192/1671) of the Aspirin group,the difference was statistically significant(P<0.05).The total efficiency of treatment in the Clopidogrel group was 96.7%,which was significantly higher than 78.2%of the Aspirin group,the difference was statistically significant(P<0.05).ECG curative effect assessment found that the total effective rate of the Clopidogrel group was 86.7%,which was significantly higher than 70.8%of the Aspirin group,the difference was statistically significant(P<0.05).In the course of treatment,the incidence of adverse reaction in the Clopidogrel group was 3.2%(76/2400), which was significantly lower than 10.7%(178/1671) in the Aspirin group,the difference was statistically significant(P<0.05).Conclusion:The clinical efficacy and safety of Clopidogrel in the treatment of stable coronary artery disease is better than Aspirin,and is worthy of clinical application.